Find your next paid study

~$75 – $3,000

Actual pay is set by the research site.

PfizerNCT07226999

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

Iambic Therapeutics, IncNCT06253871

Actual pay is set by the research site.

Phase 2

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated …

Non Small Cell Lung CancerNSCLCKRAS G12C

Ryan Gentzler, MDNCT06248606

~$75 – $3,000

Actual pay is set by the research site.

NSCLC (Non-small Cell Lung Cancer)Solid Tumor

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of …

Yuhan CorporationNCT06616766

Actual pay is set by the research site.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Adenocarcinoma+7 more

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and i…

Revolution Medicines, Inc.NCT07349537

Actual pay is set by the research site.

NSCLC (Advanced Non-small Cell Lung Cancer)

A Phase 1/2 Open-label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NHT102 (5-Azacytidine Dry Powder Formulation Delivered by a Novel Inhalation Delivery System) in Patients With Advanced Non-Small Cell Lung Cancer

There are 3 parts to this clinical trial. The goal of this clinical trial (NHT102-001) is to learn how safe NHT102 is, what dose works best, and whether it can…

Nob Hill Therapeutics, Inc.NCT07864584

Actual pay is set by the research site.

Phase 2

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Small Cell Lung Cancer (SCLC)

Alliance Foundation Trials, LLC.NCT07149363

~$75 – $2,000

Actual pay is set by the research site.

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received pl…

Yale UniversityNCT07113691

~$500 – $7,500

Actual pay is set by the research site.

Lung Cancer (NSCLC)Prostate CancerEsophageal Cancer+1 more

A Phase I, First in Human (FIH), Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Preliminary Efficacy and Immunogenicity of TJ101 for Injection in Patients With Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with …

Phrontline BiopharmaNCT07181473

Actual pay is set by the research site.

Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva)

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treat…

NSCLC, Stage IIILocally Advanced Lung Carcinoma

Jun Zhang, MD, PhDNCT04680377

~$10 – $1,125

Actual pay is set by the research site.

Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), n…

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Actual pay is set by the research site.

A2 Biotherapeutics Inc.

Phase 2

Phase IIa Trial Evaluating the Safety and Therapeutic Effect of SMS001 as an Adjuvant Therapy to Control Tumor Recurrence in Stage Ia-IIIa (N2) Non-Small Cell Lung Cancer (NSCLC) Patients

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose f…